Publications

1. Stewart CM, Siegler EL, Sakemura RL, Cox MJ, Huynh T, Kimball B, Mai L, Can I, Manriquez Roman C, Yun K, Sirpilla O, Girsch JH, Ogbodo E, Mohammed Ismail W, Gaspar-Maia A, Budka J, Kim J, Scholler N, Mattie M, Filosto S, Kenderian SS. IL-4 drives exhaustion of CD8(+) CART cells. Nat Commun. 2024 Sep 12; 15 (1):7921 Epub 2024 Sept 12
   View PubMed
2. Sakemura RL, Manriquez Roman C, Horvei P, Siegler EL, Girsch JH, Sirpilla OL, Stewart CM, Yun K, Can I, Ogbodo EJ, Adada MM, Bezerra ED, Kankeu Fonkoua LA, Hefazi M, Ruff MW, Kimball BL, Mai LK, Huynh TN, Nevala WK, Ilieva K, Augsberger C, Patra-Kneuer M, Schanzer J, Endell J, Heitmuller C, Steidl S, Parikh SA, Ding W, Kay NE, Nowakowski GS, Kenderian SS. CD19 occupancy with tafasitamab increases therapeutic index of CART19 cell therapy and diminishes severity of CRS. Blood. 2024 Jan 18; 143 (3):258-271
   View PubMed
3. Sakemura RL, Hefazi M, Cox MJ, Siegler EL, Sinha S, Hansen MJ, Stewart CM, Feigin JM, Manriquez Roman C, Schick KJ, Can I, Tapper EE, Horvei P, Adada MM, Bezerra ED, Kankeu Fonkoua LA, Ruff MW, Forsman CL, Nevala WK, Boysen JC, Tschumper RC, Grand CL, Kuchimanchi KR, Mouritsen L, Foulks JM, Warner SL, Call TG, Parikh SA, Ding W, Kay NE, Kenderian SS. AXL Inhibition Improves the Antitumor Activity of Chimeric Antigen Receptor T Cells. Cancer Immunol Res. 2023 Sep 01; 11(9):1222-1236.
   View PubMed
4. Manriquez Roman C, Sakemura RL, Kimball BL, Jin F, Khadka RH, Adada MM, Siegler EL, Johnson AJ, Kenderian SS. Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-derived Xenograft Mouse Model. J Vis Exp. 2023 Feb 10; (192).
   View PubMed
5. Sakemura R, Hefazi M, Siegler EL, Cox MJ, Larson DP, Hansen MJ, Manriquez Roman C, Schick KJ, Can I, Tapper EE, Horvei P, Adada MM, Bezerra ED, Kankeu Fonkoua LA, Ruff MW, Nevala WK, Walters DK, Parikh SA, Lin Y, Jelinek DF, Kay NE, Bergsagel PL, Kenderian SS. Targeting cancer-associated fibroblasts in the bone marrow prevents resistance to CART-cell therapy in multiple myeloma. Blood. 2022 Jun 30; 139 (26):3708-3721
   View PubMed
6. Kankeu Fonkoua LA, Sirpilla O, Sakemura R, Siegler EL, Kenderian SS. CAR T cell therapy and the tumor microenvironment: Current challenges and opportunities. Mol Ther Oncolytics. 2022 Jun 16; 25:69-77 Epub 2022 Mar 19
   View PubMed
7. Cox MJ, Manriquez Roman C, Tapper EE, Siegler EL, Chappell D, Durrant C, Ahmed O, Sinha S, Mwangi R, Scott NS, Hefazi M, Schick KJ, Horvei P, Ruff MW, Can I, Adada M, Bezerra E, Kankeu Fonkoua LA, Parikh SA, Kay NE, Sakemura R, Kenderian SS. GM-CSF disruption in CART cells modulates T cell activation and enhances CART cell anti-tumor activity. Leukemia. 2022 Jun; 36(6):1635-1645. Epub 2022 Apr 19.
   View PubMed
8. Can I, Cox MJ, Siegler EL, Sakemura R, Kenderian SS. Challenges of chimeric antigen receptor T-cell therapy in chronic lymphocytic leukemia: lessons learned. Exp Hematol. 2022 Apr; 108:1-7. Epub 2022 Feb 10.
   View PubMed
9. Girsch JH, Mejia Plazas MC, Olivier A, Farah M, Littlefield D, Behl S, Punia S, Sakemura R, Hemsath JR, Norgan A, Enninga EAL, Johnson EL, Chakraborty R. Host-Viral Interactions at the Maternal-Fetal Interface. What We Know and What We Need to Know. Frontiers (Boulder). 2022 Mar; 2. Epub 2022 Mar 24.
   View PubMed
10. Sakemura R, Cox MJ, Bansal A, Roman CM, Hefazi M, Vernon CJ, Glynn DL, Pandey MK, DeGrado TR, Siegler EL, Kenderian SS. Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography. J Vis Exp. 2022 Feb 17; (180).
    View PubMed
11. Miyao K, Yokota H, Sakemura RL. Is CD19-directed chimeric antigen receptor T cell therapy a smart strategy to combat central nervous system lymphoma? Front Oncol. 2022; 12:1082235 Epub 2023 Jan 05
    View PubMed
12. Can I, Cox MJ, Siegler EL, Sakemura R, Kenderian SS. Challenges of chimeric antigen receptor T-cell therapy in chronic lymphocytic leukemia: lessons learned. Experimental Hematology. 2022; 108:1-7
    
13. Sakemura R, Bansal A, Siegler EL, Hefazi M, Yang N, Khadka RH, Newsom AN, Hansen MJ, Cox MJ, Manriquez Roman C, Schick KJ, Can I, Tapper EE, Nevala WK, Adada MM, Bezerra ED, Kankeu Fonkoua LA, Horvei P, Ruff MW, Parikh SA, Pandey MK, DeGrado TR, Suksanpaisan L, Kay NE, Peng KW, Russell SJ, Kenderian SS. Development of a Clinically Relevant Reporter for Chimeric Antigen Receptor T-cell Expansion, Trafficking, and Toxicity. Cancer Immunol Res. 2021 Sep; 9(9):1035-1046. Epub 2021 Jul 08.
    View PubMed
14. Sakemura R, Cox MJ, Hefazi M, Siegler EL, Kenderian SS. Resistance to CART cell therapy: lessons learned from the treatment of hematological malignancies. Leuk Lymphoma. 2021 Sep; 62(9):2052-2063. Epub 2021 Mar 08.
    View PubMed
15. Cox MJ, Lucien F, Sakemura R, Boysen JC, Kim Y, Horvei P, Manriquez Roman C, Hansen MJ, Tapper EE, Siegler EL, Forsman C, Crotts SB, Schick KJ, Hefazi M, Ruff MW, Can I, Adada M, Bezerra E, Kankeu Fonkoua LA, Nevala WK, Braggio E, Ding W, Parikh SA, Kay NE, Kenderian SS. Leukemic extracellular vesicles induce chimeric antigen receptor T cell dysfunction in chronic lymphocytic leukemia. Mol Ther. 2021 Apr 7; 29 (4):1529-1540 Epub 2021 Jan 01
    View PubMed
16. Sakemura R, Can I, Siegler EL, Kenderian SS. In vivo CART cell imaging: Paving the way for success in CART cell therapy. Mol Ther Oncolytics. 2021 Mar 26; 20:625-633. Epub 2021 Mar 05.
    View PubMed
17. Temesgen Z, Assi M, Shweta FNU, Vergidis P, Rizza SA, Bauer PR, Pickering BW, Razonable RR, Libertin CR, Burger CD, Orenstein R, Vargas HE, Palraj R, Dababneh AS, Chappell G, Chappell D, Ahmed O, Sakemura R, Durrant C, Kenderian SS, Badley AD. GM-CSF Neutralization With Lenzilumab in Severe COVID-19 Pneumonia: A Case-Cohort Study. Mayo Clin Proc. 2020 Nov; 95 (11):2382-2394 Epub 2020 Sept 03
    View PubMed
18. Temesgen Z, Assi M, Vergidis P, Rizza SA, Bauer PR, Pickering BW, Razonable RR, Libertin CR, Burger CD, Orenstein R, Vargas HE, Varatharaj Palraj BR, Dababneh AS, Chappell G, Chappell D, Ahmed O, Sakemura R, Durrant C, Kenderian SS, Badley A. First Clinical Use of Lenzilumab to Neutralize GM-CSF in Patients with Severe COVID-19 Pneumonia. medRxiv 2020 Jun 14 Epub 2020 June 14
    View PubMed
19. Sterner RM, Cox MJ, Sakemura R, Kenderian SS. Using CRISPR/Cas9 to Knock Out GM-CSF in CAR-T Cells. J Vis Exp. 2019 Jul 22; (149).
    View PubMed
20. Khadka RH, Sakemura R, Kenderian SS, Johnson AJ. Management of cytokine release syndrome: an update on emerging antigen-specific T cell engaging immunotherapies. Immunotherapy. 2019 Jul; 11 (10):851-857 Epub 2019 June 04
    View PubMed
21. Koyama D, Murata M, Hanajiri R, Akashi T, Okuno S, Kamoshita S, Julamanee J, Takagi E, Miyao K, Sakemura R, Goto T, Terakura S, Nishida T, Kiyoi H. Quantitative Assessment of T Cell Clonotypes in Human Acute Graft-versus-Host Disease Tissues. Biol Blood Marrow Transplant. 2019 Mar; 25 (3):417-423 Epub 2018 Oct 22
    View PubMed
22. Sterner RM, Sakemura R, Cox MJ, Yang N, Khadka RH, Forsman CL, Hansen MJ, Jin F, Ayasoufi K, Hefazi M, Schick KJ, Walters DK, Ahmed O, Chappell D, Sahmoud T, Durrant C, Nevala WK, Patnaik MM, Pease LR, Hedin KE, Kay NE, Johnson AJ, Kenderian SS. GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts. Blood. 2019 Feb 14; 133 (7):697-709 Epub 2018 Nov 21
    View PubMed
23. Shimizu R, Sakemura R, Iwata S, Hayakawa H, Miyao K, Kajiguchi T. [Pneumocystis pneumonia prophylaxis with low-dose trimethoprim/sulfamethoxazole during rituximab-containing chemotherapy]. Rinsho Ketsueki. 2019; 60 (5):365-371
    View PubMed
24. Mizuta S, Sawa M, Tsurumi H, Matsumoto K, Miyao K, Hara T, Takahashi T, Sakemura R, Kojima H, Kohno A, Oba MS, Morita S, Sakamoto J, Emi N. Plasma concentrations of dasatinib have a clinical impact on the frequency of dasatinib dose reduction and interruption in chronic myeloid leukemia: an analysis of the DARIA 01 study. Int J Clin Oncol. 2018 Oct; 23 (5):980-988 Epub 2018 May 29
    View PubMed
25. Miyao K, Terakura S, Okuno S, Julamanee J, Watanabe K, Hamana H, Kishi H, Sakemura R, Koyama D, Goto T, Nishida T, Murata M, Kiyoi H. Introduction of Genetically Modified CD3zeta Improves Proliferation and Persistence of Antigen-Specific CTLs. Cancer Immunol Res. 2018 Jun; 6 (6):733-744 Epub 2018 Apr 13
    View PubMed
26. Sakemura R, Hayakawa H, Iida H, Ito M, Kajiguchi T. Successful Treatment of a Case of Late-onset Colitis after Umbilical Cord Transplantation with Metronidazole: A Case Report and Literature Review. Intern Med. 2017 Dec 1; 56 (23):3219-3223 Epub 2017 Oct 11
    View PubMed
27. Yokohata E, Kuwatsuka Y, Ohashi H, Terakura S, Kawashima N, Seto A, Kurahashi S, Ozawa Y, Goto T, Imahashi N, Nishida T, Miyao K, Sakemura R, Kato T, Sawa M, Kohno A, Sao H, Iida H, Kiyoi H, Naoe T, Miyamura K, Murata M. Impact of T-cell chimerism on relapse after cord blood transplantation for hematological malignancies: Nagoya Blood and Marrow Transplantation Group study. Bone Marrow Transplant. 2017 Apr; 52 (4):612-614 Epub 2017 Jan 09
    View PubMed
28. Koyama D, Murata M, Hanajiri R, Okuno S, Kamoshita S, Julamanee J, Takagi E, Hirano D, Miyao K, Sakemura R, Goto T, Hayakawa F, Seto A, Ozawa Y, Miyamura K, Terakura S, Nishida T, Kiyoi H. High incidence of extensive chronic graft-versus-host disease in patients with the REG3A rs7588571 non-GG genotype. PLoS One. 2017; 12 (9):e0185213 Epub 2017 Sept 25
    View PubMed
29. Miyao K, Sawa M, Kurata M, Suzuki R, Sakemura R, Sakai T, Kato T, Sahashi S, Tsushita N, Ozawa Y, Tsuzuki M, Kohno A, Adachi T, Watanabe K, Ohbayashi K, Inagaki Y, Atsuta Y, Emi N. A multicenter phase 2 study of empirical low-dose liposomal amphotericin B in patients with refractory febrile neutropenia. Int J Hematol. 2017 Jan; 105 (1):79-86 Epub 2016 Sept 30
    View PubMed
30. Sakemura R, Hiraga J, Kitagawa S, Ito M, Kajiguchi T, Mizuno S. Interdigitating dendritic cell sarcoma successfully treated with ABVD therapy in which serum CEA levels correlated with disease activity. Rinsho Ketsueki. 2017; 58 (4):292-297
    View PubMed
31. Goto T, Nishida T, Takagi E, Miyao K, Koyama D, Sakemura R, Hanajiri R, Watanabe K, Imahashi N, Terakura S, Murata M, Kiyoi H. Programmed Death-Ligand 1 on Antigen-presenting Cells Facilitates the Induction of Antigen-specific Cytotoxic T Lymphocytes: Application to Adoptive T-Cell Immunotherapy. J Immunother. 2016 Oct; 39 (8):306-15
    View PubMed
32. Sakemura R, Terakura S, Watanabe K, Julamanee J, Takagi E, Miyao K, Koyama D, Goto T, Hanajiri R, Nishida T, Murata M, Kiyoi H. A Tet-On Inducible System for Controlling CD19-Chimeric Antigen Receptor Expression upon Drug Administration. Cancer Immunol Res. 2016 Aug; 4 (8):658-68 Epub 2016 June 21
    View PubMed
33. Hanajiri R, Murata M, Sugimoto K, Murase M, Sakemura R, Goto T, Watanabe K, Imahashi N, Terakura S, Ohashi H, Akatsuka Y, Kurahashi S, Miyamura K, Kiyoi H, Nishida T, Naoe T. Integration of humoral and cellular HLA-specific immune responses in cord blood allograft rejection. Bone Marrow Transplant. 2015 Sep; 50 (9):1187-94 Epub 2015 June 01
    View PubMed
34. Imahashi N, Ohashi H, Terakura S, Miyao K, Sakemura R, Kato T, Sawa M, Yokohata E, Kurahashi S, Ozawa Y, Nishida T, Kiyoi H, Watamoto K, Kohno A, Kasai M, Kato C, Iida H, Naoe T, Miyamura K, Murata M, Nagoya Blood and Marrow Transplantation Group. Chimerism status after unrelated donor bone marrow transplantation with fludarabine-melphalan conditioning is affected by the melphalan dose and is predictive of relapse. Ann Hematol. 2015 Jul; 94 (7):1139-48 Epub 2015 Feb 15
    View PubMed
35. Watanabe K, Terakura S, Martens AC, van Meerten T, Uchiyama S, Imai M, Sakemura R, Goto T, Hanajiri R, Imahashi N, Shimada K, Tomita A, Kiyoi H, Nishida T, Naoe T, Murata M. Target antigen density governs the efficacy of anti-CD20-CD28-CD3 zeta chimeric antigen receptor-modified effector CD8+ T cells. J Immunol. 2015 Feb 1; 194 (3):911-20 Epub 2014 Dec 17
    View PubMed
36. Imahashi N, Nishida T, Goto T, Terakura S, Watanabe K, Hanajiri R, Sakemura R, Imai M, Kiyoi H, Naoe T, Murata M. Simple and efficient generation of virus-specific T cells for adoptive therapy using anti-4-1BB antibody. J Immunother. 2015 Feb-Mar; 38 (2):62-70
    View PubMed
37. Miyao K, Sakemura R, Imai K, Sakai T, Tsushita N, Kato T, Niimi K, Ono Y, Sawa M. Upfront autologous stem-cell transplantation with melphalan, cyclophosphamide, etoposide, and dexamethasone (LEED) in patients with newly diagnosed primary central nervous system lymphoma. Int J Hematol. 2014 Aug; 100 (2):152-8 Epub 2014 June 20
    View PubMed